v3.26.1
Note 2 - Summary of Significant Accounting Policies (Details Textual)
12 Months Ended
Jun. 06, 2025
USD ($)
Mar. 20, 2020
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Aug. 05, 2025
USD ($)
Oct. 22, 2021
Accounts Receivable, Allowance for Credit Loss, Current     $ 700,000 $ 97,000    
Credit Loss Expense     3,886,000 0    
Inventory Valuation Reserves     0 0    
Number of Patents Acquired           3
Income (Loss) from Equity Method Investments     (14,000) (5,000)    
Contract with Customer, Liability     280,000 0    
Customer Deposit Liability, Current     189,000 90,000    
Unrecognized Tax Benefits     $ 0 0    
Operating Lease, Weighted Average Discount Rate, Percent     18.00%      
Operating Lease, Right-of-Use Asset     $ 1,028,000 992,000    
Operating Lease, Liability     1,074,000 1,027,000    
Finance Lease, Right-of-Use Asset, after Accumulated Amortization     $ 338,000 451,000    
Minimum [Member]            
Property, Plant and Equipment, Useful Life (Year)     3 years      
Maximum [Member]            
Property, Plant and Equipment, Useful Life (Year)     10 years      
Canadian Government Grants [Member] | Minimum [Member]            
Grant Term (Month)     6 months      
Canadian Government Grants [Member] | Maximum [Member]            
Grant Term (Month)     18 months      
BioLargo Water [Member]            
Customer Deposit Liability, Current     $ 80,000 76,000    
ONM [Member]            
Customer Deposit Liability, Current     $ 109,000 14,000    
Odin Co Ltd [Member]            
Payments to Acquire Interest in Joint Venture   $ 100,000        
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage   40.00% 40.00%      
Income (Loss) from Equity Method Investments     $ (14,000) (5,000)    
Odin Co Ltd [Member] | Tomorrow Water [Member]            
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage   30.00%        
Odin Co Ltd [Member] | BKT and Tomorrow Water [Member]            
Payments to Acquire Interest in Joint Venture   $ 150,000        
Clyra Medical Technologies [Member]            
Finance Lease, Right-of-Use Asset, after Accumulated Amortization     338,000 451,000    
Finance Lease, Liability     $ 360,000 $ 448,000    
Subsidiary, Ownership Percentage, Noncontrolling Owner     52.00% 47.00%    
BioLargo Engineering, Science & Technologies, LLC [Member]            
Subsidiary, Ownership Percentage, Noncontrolling Owner     30.00% 26.00%    
BioLargo Energy Technologies, Inc (BETI) [Member]            
Subsidiary, Ownership Percentage, Noncontrolling Owner     5.00% 4.00%    
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member]            
Number of Major Customers     1 1    
Customer Concentration Risk [Member] | Accounts Receivable [Member]            
Number of Major Customers       1    
Royalty Receivable [Member]            
Financing Receivable, before Allowance for Credit Loss         $ 463,520  
Pooph Inc. Receivable [Member]            
Credit Loss Expense     $ 3,886,000      
Notes Receivable, Write-off     3,764,000      
Accounts Receivable, Allowance for Credit Loss, Writeoff     $ 0 $ 0    
Financial Asset, Past Due [Member] | Product Invoice Receivable [Member]            
Financing Receivable, before Allowance for Credit Loss $ 2,385,468          
Receivable with Imputed Interest, Effective Yield (Interest Rate) 10.00%          
Financial Asset, Past Due [Member] | Royalty Receivable [Member]            
Financing Receivable, before Allowance for Credit Loss $ 1,378,141